Meng MA of risk of tapering MTX from combo with bDMARD/tsDMARD in RA in remission. RR 0.90 (95% CI 0.84, 0.97) for maintaining remission over maximum 18 months. Authors conclude little risk to stopping - I disagree 10% is >0. @RheumNow #ACR22 Abstr#0916
Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis - ACR Meeting Abstracts
